MYCN and neoplasm: Unexpectedly, a therapeutic combination of an HDAC inhibitor (SAHA) and a novel pyridobenzimidazole (SE486-11) had profound anti-tumour effects and synergistically bound USP5, significantly reducing both USP5 and MYCN levels (Fig. 6c).